Alistair Irvine - Kuros Biosciences Executive

All Insiders . USA . 
Stock . Kuros Biosciences AG . Stakeholders . Insider . Alistair Irvine
CSBTF Stock  USD 22.05  0.55  2.43%   

Executive

Dr. Alistair Irvine is Member of the Management Board, Chief Business Officer at Kuros Biosciences Ltd since January 8, 2016. He joined Kuros as Director of Business Development in September 2006 following a period working as a technical and commercial consultant to the biotechnology industry. Prior to his work as a consultant he was Deputy Director of Research and Research Operations Manager at Innovata plc, where in addition to managing research programs in the fields of gene expression, cell culture, polymer science and oncology he also played a major role in business development. He has also held the positions of Head of Biology at ML Laboratories plc, Subdivisional Head at Cobra Therapeutics Ltd, Group Leader at Cobra Therapeutics Ltd and Senior Scientist with Therexsys Ltd. He has worked in the biotechnologymedtech industry for over 20 years since 2016.
Age 54
Tenure 9 years
Professional MarksPh.D
Phone41 44 733 4747
Webhttps://www.kuros.ch
Irvine holds a PhD in Molecular Biology from the University of Sheffield and a BSc in Biochemistry from the University of Edinburgh.

Kuros Biosciences Management Efficiency

The company has return on total asset (ROA) of (0.0667) % which means that it has lost $0.0667 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1409) %, meaning that it generated substantial loss on money invested by shareholders. Kuros Biosciences' management efficiency ratios could be used to measure how well Kuros Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.
Kuros Biosciences AG has accumulated 2.21 M in total debt with debt to equity ratio (D/E) of 0.03, which may suggest the company is not taking enough advantage from borrowing. Kuros Biosciences has a current ratio of 2.85, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Kuros Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Kuros Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Kuros Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Kuros to invest in growth at high rates of return. When we think about Kuros Biosciences' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Jason BeachStryker
N/A
Teri LawverDexCom Inc
57
Christine McCauleyEdwards Lifesciences Corp
60
Daniel LippisEdwards Lifesciences Corp
48
Dragana BunjevacStryker
N/A
Arnold JDEdwards Lifesciences Corp
66
Dirksen LehmanEdwards Lifesciences Corp
N/A
Sabina EwingAbbott Laboratories
51
Finn HaleyEdwards Lifesciences Corp
N/A
Stacey StewartDexCom Inc
N/A
Mark WilterdingEdwards Lifesciences Corp
N/A
Michael ComillaAbbott Laboratories
N/A
Mike PanosStryker
N/A
MD FACCEdwards Lifesciences Corp
N/A
Michael BrownDexCom Inc
55
Matthew DolanDexCom Inc
44
Andrew DahlEdwards Lifesciences Corp
48
Jeffrey MBABoston Scientific Corp
59
Arnold PinkstonEdwards Lifesciences Corp
65
Stuart SilkStryker
N/A
Melissa BrotzAbbott Laboratories
N/A
Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. It has collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. KUROS BIOSCIENCES operates under Biotechnology classification in the United States and is traded on PNK Exchange. It employs 58 people. Kuros Biosciences AG [CSBTF] is a Pink Sheet which is traded between brokers over the counter.

Management Performance

Return On Equity-0.14
Return On Asset-0.0667

Kuros Biosciences Leadership Team

Elected by the shareholders, the Kuros Biosciences' board of directors comprises two types of representatives: Kuros Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kuros. The board's role is to monitor Kuros Biosciences' management team and ensure that shareholders' interests are well served. Kuros Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kuros Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
BSc BS, CEO Director
Florence Groot, Head Devel
Philippe Saudan, Chief Scientific Officer and VP
Oliver Kronenberg, Legal Counsel
MS DO, VP Affairs
Christopher Fair, Chief Officer
MBA MBA, Chief Officer
Alistair Irvine, Member of the Management Board, Chief Business Officer
Charlie Campion, VP Sales
John Griffin, VP Sales

Kuros Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Kuros Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-0.14
Return On Asset-0.0667
Profit Margin(0.74) %
Operating Margin(0.64) %
Current Valuation40.53 M
Shares Outstanding36.54 M
Shares Owned By Insiders35.33 %
Shares Owned By Institutions16.83 %
Price To Earning0.33 X
Price To Book0.79 X

Currently Active Assets on Macroaxis

VVisa Class A
CRMSalesforce
CRMSalesforce
MSFTMicrosoft
VVisa Class A

Other Information on Investing in Kuros Pink Sheet

Kuros Biosciences financial ratios help investors to determine whether Kuros Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Kuros with respect to the benefits of owning Kuros Biosciences security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY